Information Provided By: 
Fly News Breaks for September 6, 2017
INSM
Sep 6, 2017 | 08:35 EDT
Baird analyst Brian Skorney raised his price target on Insmed to $32 from $23 following the results of its long-awaited Phase 3 CONVERT data. The analyst noted its primary endpoints were better than expected. The secondary endpoints were not as positive, but he does not believe that will affect its approvability. Skorney reiterated his Outperform rating on Insmed shares.
News For INSM From the Last 2 Days
There are no results for your query INSM
